CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,855.00
0.00 (0.00%)
At close: Sep 11, 2026

CJ Bioscience Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-22,327-24,005-32,838-22,913-34,913-19,272
Depreciation & Amortization
3,8244,0134,3215,1463,9001,562
Loss (Gain) From Sale of Assets
293.74638.74-10.89-8,718366.99-10.43
Asset Writedown & Restructuring Costs
-----170.67
Stock-Based Compensation
---141.5543.83555.76
Provision & Write-off of Bad Debts
-----105.27
Other Operating Activities
1,3431,7701,8461,8803,3759,460
Change in Accounts Receivable
-89.84-345.9188.9142.18-70.3-191.24
Change in Inventory
-79.22-56.3729.07-81.6669.66-231.19
Change in Accounts Payable
36.88157.4998.01-213.8448.91-421.5
Change in Unearned Revenue
31.7835.4928.67119.84211.4953.71
Change in Other Net Operating Assets
-2,801-5,624-1,324-401.615,505-218.1
Operating Cash Flow
-19,768-23,416-27,760-24,899-20,963-8,437
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-19.76-10.66-377.59-4,924-4,145-952.65
Sale of Property, Plant & Equipment
86.3199.5226.3433,11685.0910.45
Cash Acquisitions
-----6,239-
Sale (Purchase) of Intangibles
-58.27314.73-206.02-11,493-725.5-26.1
Investment in Securities
12,50026,500-67,0000.2118,0187,158
Other Investing Activities
----0171.58262.42
Investing Cash Flow
12,50826,904-67,55716,6997,1656,453

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-763.731,7051,3052,636-
Total Debt Issued
800.33763.731,7051,3052,636-
Long-Term Debt Repaid
--1,843-1,864-23,077-1,414-22,768
Net Debt Issued (Repaid)
-1,104-1,079-159.04-21,7721,222-22,768
Issuance of Common Stock
--39,97044,9775073,479
Other Financing Activities
-369.15-362.62-311.73-260.87-280.02-0
Financing Cash Flow
-1,474-1,44239,49922,944992.1850,711

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
1.39-15.7932.1326.7469.6978.4
Miscellaneous Cash Flow Adjustments
-0-0000-
Net Cash Flow
-8,7322,030-55,78614,772-12,73748,805

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-19,788-23,427-28,138-29,823-25,108-9,390
Free Cash Flow Growth
------
Free Cash Flow Margin
-538.13%-634.44%-811.70%-534.93%-616.19%-215.22%
Free Cash Flow Per Share
-1514.86-1793.05-3034.18-4210.07-4271.74-2208.24
Levered Free Cash Flow
-10,918-16,393-16,913-32,209-17,249-6,708
Unlevered Free Cash Flow
-10,580-16,055-16,546-31,633-15,522-3,603

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
369.15362.62311.73190.8730.02361.12
Cash Income Tax Paid
-38.6570.741.48141.565.3
Change in Working Capital
-2,901-5,833-1,079-435.095,765-1,008